STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid

Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(15min)CommentsSummarySTAAR Surgical Company has seen a dramatic valuation reset, now trading at a $1bn market cap after failed acquisition talks and underwhelming US growth.Q1 2026 net sales are expected to exceed $90m, driven by a strong rebound in China and signaling potential for record annual revenues.Despite operational challenges and competitive pressures, STAA's proprietary Collamer lens and expanded US indications provide incremental growth opportunities.I expect STAA to achieve over $400m in 2026 revenue and return to profitability, supporting a valuation between $1.5bn–$2bn by early 2027.Looking for a helping hand in the market? Members of Haggerston BioHealth get exclusive ideas and guidance to navigate any climate. Learn More » designer491/iStock via Getty Images Investment Overview It's been just over two years since I last covered STAAR Surgical Company (STAA) aka "Staar" in a note for Seeking Alpha. I had been covering the company since my first note in This article was written byEdmund Ingham14.85K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.